Onyx Seeks Suitors After Rejecting Amgen’s Bid

July 1 (Bloomberg) -- Onyx Pharmaceuticals, the maker of the cancer drug Nexavar, said it is in contact with other possible acquirers after rejecting an unsolicited $120-a-share cash takeover bid from Amgen Onyx shares surged. Dominic Chu reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)
Rate Rise: Breaking Down the Fed Minutes
00:40 - David Bloom, global head of FX strategy at HSBC, and Bloomberg Intelligence's Jamie Murray discuss the Fed Minutes and the possibility of a rate hike. They speak to Bloomberg's Anna Edwards on "Countdown." (Source: Bloomberg)
  • Angela Merkel: Nobel Peace Prize Winner?
  • DSV Buys UTi Worldwide for $1.35B
  • Why 4Q Will Be Pivotal for American Companies